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Major operations performed or assisted at by registrars over three months
Without help Under supervision Assisted at
Elective Emergency Elective Emergencv Elective Emergency
Median 13 1 1 3 0 3 0
Range 1-40 2-26 0-20 0-2 0-13 0-6
(25%), and inadequate by three (18%). Two stated that
free discussion about management of patients was not
encouraged, and one individual replied that this was
tolerated but not encouraged.
Twelve registrars (75%) were actively encouraged to
perform research, but fewer than half of these were
supervised. One registrar considered the research
opportunities of his post to be good.
Seven (44%) said that they would have recom-
mended their post to a colleague and eight (50%) had
some reservations. One individual did not consider his
post suitable for registrar training. The most frequent
criticism was that too little time was allocated for
pursuing a research interest.
Comment
Effective audit depends on a three part cycle of
reviewing and setting standards, comparing these
standards with observed practice, and implementing
appropriate change. In the Mersey region there is
no organised training programme or consensus on
standards of training with which to compare the results
of this audit. It is therefore impossible to comment on
their acceptability.
On average, in this region, a registrar performs one
major elective operation every week, but supervised
training occurs only once each month. With the
current surplus of highly experienced registrars it is
not surprising.that some consultants leave their juniors
to perform major elective procedures without close
supervision. One supervised operation each month is,
however, probably inadequate training for most
registrars. Supervision by consultants of emergency
surgery is uncommon in the region.
At present the published record of a candidate's
research experience and a higher degree are the two
most important factors in obtaining promotion. While
these yardsticks of ability continue to be applied the
trainer must provide encouragement, ideas, advice,
and free time for research so that his registrar may
impress the next interview panel with his academic
achievements. Only then will he be allowed to display
his clinical skills at a higher level. Only one general
surgical post in the Mersey region was considered to
provide good opportunities and training in research.
Many registrars seemed satisfied with the quality of
the training they had received. Most of the deficiencies
cited could easily be corrected by more contact with a
nominated supervising consultant and the allocation of
free time for research.
1 Shaw CD. 4: Acceptability of audit. Br Medj 1980;280:1443-6.
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Effect of amiodarone on
circulating antithyroid
antibodies
M Safran, E Martino, F Aghini-Lombardi,
L Bartalena, S Balzano, A Pinchera,
L E Braverman
Long term treatment with amiodarone, a benzofuran
antiarrhythmic drug that contains iodine, may cause
hyperthyroidism and hypothyroidism induced by
iodine. 2 It has been suggested that amiodarone itself
induces thyroid antibodies and that this may account
for the high incidence of thyroid dysfunction in
patients receiving this drug. We prospectively evalu-
ated the development of thyroid autoantibodies in
patients who were receiving long term amiodarone
treatment.
Patients, methods, and results
Euthyroid patients were evaluated before, during,
and after amiodarone treatment. Thirty one patients
(21 men, 10 women; mean (SD) age 53 (15) years) lived
in Pisa and Cagliari, Italy, regions fairly deficient in
iodine, and 16 patients (11 men, five women; age 57
(14) years) lived in Worcester, Massachusetts, a region
of iodine sufficiency. All patients were evaluated
clinically and had tests of thyroid function, including
serum concentrations of triiodothyronine and thy-
roxine by radioimmunoassay, thyroid stimulating
hormone by sensitive immunoradiometric assay, and
antimicrosomal and antithyroglobulin antibodies by
passive haemagglutination with commercial kits (Fuji-
zoki Pharmaceutical Ltd, Japan (Italy) and Ames
Company, Miles Laboratory, Indiana (Worcester)).
Before receiving amiodarone 10 patients from Pisa and
Cagliari and four patients from Worcester had non-
toxic goitre.
The table shows the results of the antibody studies.
Only two of the patients from Pisa and Cagliari,
both euthyroid with non-toxic goitres, had detectable
antithyroid antibodies before beginning treatment
with amiodarone and continued to have detectable
antibodies (antimicrosomal only) while receiving
amiodarone. One additional patient had detectable
antimicrosomal antibodies (1:400) on day 86 of treat-
ment but was subsequently found to have a negative
titre on day 144. Another patient, who had negative
titres of antibodies and had received treatment with
radioactive iodine for diffuse toxic goitre three years
previously, developed hypothyroidism after 119 days
of treatment. One other patient developed hyper-
thyroidism after 2-5 years of treatment with amio-
darone. In this patient antibodies, obtained 15 times
during and after treatment, wei detectable (anti-
microsomal 1:100) only twice after amiodarone was
stopped. In 29 of the 31 patients thyroid dysfunction
did not occur.
Four of the 16 patients from Worcester had detect-
able antimicrosomal antibodies before treatment
with amiodarone. Two of the four patients who had
detectable antimicrosomal antibodies (1:100) before
amiodarone treatment had negative antibody titres on
days 191 and 225 of treatment, respectively. Though
two patients developed small non-toxic goitres while
taking amiodarone, none developed thyroid dys-
function or antibodies.
Twenty patients from Pisa and Cagliari were evalu-
ated one to 35 months after withdrawing amiodarone.
Two patients had detectable antibodies during this
time, one of whom is described above. The second
patient had detectable antimicrosomal antibodies
(1:100) 660 days after stopping amiodarone treatment
but had no detectable antibodies on two subsequent
occasions.
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Thyroid antibodies in patients before and during long term amiodarone treatment
No of days of treatment with
Positive thyroid antibodies* amiodarone
Before During
n amiodarone amiodarone Mean (SD) Range
Pisa and Cagliari:
Short term (--three months) 19 1 1 41(26) 13-98
Long term (-four months) 12 1 2t 284 (266) 119-1078
Worcester:
Short term (-three months) 1 0 0 90
Long term (-four months) 15 4 2 299 (91) 174-413
*Antibody titres greater than or equal to 1:100 were considered to be positive.
tOne patient developed intermittently positive antimicrosomal antibodies.
Comment
Evidence of thyroid autoimmunity has often been
noted in patients who develop hypothyroidism while
receiving amiodarone.2 Between 30% and 50% of
patients who have hypothyroidism induced by amio-
darone iodine have antithyroid antibodies.' 2 Anti-
thyroid antibodies are less common in patients who
have hyperthyroidism induced by amiodarone iodine.
Monteiro et al reported the development of antimicro-
somal antibodies in six of 13 patients treated with
amiodarone for one month. Two of these patients had
slightly increased serum concentrations of thyroid
stimulating hormone, and all were euthyroid with
negative antibody titres six months after the amio-
darone had been withdrawn. Rabinowe et al noted a
high prevalence (60%) of antimicrosomal antibodies in
10 patients who received amiodarone, but no data are
available for these patients before treatment.4 One
of their patients developed hyperthyroidism while
receiving amiodarone and showed a considerable
increase in immune region associated antigen positive
T cells, often found in patients who have Graves'
disease, which resolved within three weeks of with-
drawing the amiodarone.
The results of our prospective study, however,
which included patients treated with amiodarone for
both short and long periods and from regions of
differing ambient iodine intake show that amiodarone
treatment does not seem to be associated with an
increased incidence of antithyroid antibodies.
This study was partly supported by a CNR grant, Rome,
and grant No DK 18918, NIDDK, Bethesda, MD.
I Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake
and thyroid dysfunction during chronic amiodarone therapy. Attn Iniern Med
1984;101:28-34.
2 Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone iodine-induced
hypothyroidism: risk factors and follow-up in 28 cases. flin Endocrinol
1987;26:27-37.
3 Monteiro E, Galvao-Teles A, Santos ML, et al. Antithyroid antibodies as an
earls marker for thsroid disease induced by amiodarone. Br Med J
1986;292:227-8.
4 Rabinowe SL, Larsen PR, Antman EM, et al. Amiodarone therapy and
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5 Martino F, Aghini-Lombardi F, Mariotti S, et al. Amiodarone: a common
source of iodine-induced thyrotoxicosis. Hormone Res 1987;26: 158-71.
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Respiratory muscle weakness in
Addison's disease
Anne Mier, Clare Laroche, John Wass,
Malcolm Green
Patients with Addison's disease may rarely present
with wheezing due to asthma.' More commonly they
have non-specific symptoms such as weakness,
dizziness, and weight loss. We describe a patient who
presented with dyspnoea on exertion that was related
to severe respiratory muscle weakness.
Case report
A 63 year old retired caterer presented with a two
month history of dry cough and wheezing. Her
tolerance ofexercise was 400 metres on the flat, she had
no orthopnoea but became breathless on stairs. She
smoked 20 cigarettes a day, had lost 6 kg over the past
year, but denied any abdominal pain, anorexia, or
blackouts. Her menstruation had been normal until
the age of 50, and she had one son aged 36.
On examination she was deeply tanned with pig-
mented palmar creases and intraoral pigmentation.
She had no axillary hair and scanty pubic hair. Her
blood pressure was 95/70 mm Hg when supine and
85/75 mmHg when standing. She had a widespread
expiratory wheeze; peak flow was 150 I/min, forced
expiratory volume in one second 1 3 1, and forced vital
capacity 1-5 1. The plasma concentration of sodium
was 129 mmol/l, potassium 4-5 mmol/l, and urea
8-6 mmol/l; haemoglobin was 136 g/l, white cell count
5 05x102/1 (8% eosinophils), and erythrocyte
sedimentation rate 9 mm in first hour. The results of
tests of liver and thyroid function were normal. Plasma
cortisol concentrations during three short tests with
tetracosactrin were 120 nmol/l, 140 nmol/l, and
120 nmol/l, the lack of a cortisol response being
confirmed by a long test with tetracosactrin. Luteinis-
ing and follicle stimulating hormone concentrations
were both in the menopausal range (>50 U/1), and
adrenocorticotrophic hormone was 266 7 pmol/l
(normal 2 2-17 8 pmol/l). Respiratory muscle studies2
showed low maximal static expiratory mouth pressure
(34 cm H20; normal >32 cm H20), low maximal static
inspiratory mouth pressure (14 cm H20; normal
>24 cm H20), and reduced transdiaphragmatic
pressure during maximal sniffs3 (48 cm H20; normal
>70 cm H20). Phrenic nerve conduction times were
9 ms (normal 5-9 5 ms). Maximal voluntary contrac-
tion of the quadriceps muscles was 9 kg (normal
>29 kg).
Full replacement treatment with hydrocortisone
acetate was started. Ten months later her breathless-
ness had improved such that she was able to climb two
flights of stairs. Peak flow had increased to 315 1/min,
forced expiratory volume in one second to 1-6 1, and
forced vital capacity to 2 5 1. Maximal static expiratory
mouth pressure had increased to 45 cm H20, maximal
static inspiratory mouth pressure to 20 cm H20, and
transdiaphragmatic pressure during maximal sniffs to
75 cm H20. Phrenic nerve conduction times were
unchanged. Maximal voluntary contraction of the
quadriceps muscles increased to 22 kg.
Comment
In Addison's disease generalised fatigue is common
and is usually attributed to non-specific malaise rather
than muscle weakness. Our patient, however, showed
evidence of weakness in both respiratory and quadri-
ceps muscles, suggesting that all skeletal muscles were
affected. Phrenic neuropathy was excluded by the
finding of normal conduction times in the phrenic
nerve. Although electrolyte disturbances may have
partially contributed, weakness in the respiratory
muscles probably resulted mainly from myopathy.
Thus just as steroid myopathy may be induced by
Cushing's syndrome or by excessive corticosteroid
administration, so a lack of corticosteroid also seems to
result in muscle weakness and myopathy.
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